Advances in computational approaches in identifying synergistic drug combinations

Accumulated empirical clinical experience, supported by animal or cell line models, has initiated efforts of predicting synergistic combinatorial drugs with more-than-additive effect compared with the sum of the individual agents. Aiming to construct better computational models, this review started from the latest updated data resources of combinatorial drugs, then summarized the reported mechanism of the known synergistic combinations from aspects of drug molecular and pharmacological patterns, target network properties and compound functional annotation. Based on above, we focused on the main in silico strategies recently published, covering methods of molecular modeling, mathematical simulation, optimization of combinatorial targets and pattern-based statistical/learning model. Future thoughts are also discussed related to the role of natural compounds, drug combination with immunotherapy and management of adverse effects. Overall, with particular emphasis on mechanism of action of drug synergy, this review may serve as a rapid reference to design improved models for combinational drugs.

[1]  B Xie,et al.  Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. , 2009, Drug discovery today.

[2]  Bo Zhang,et al.  A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway , 2010, BMC Systems Biology.

[3]  Xiaobo Zhou,et al.  Systems Modeling of Anti-apoptotic Pathways in Prostate Cancer: Psychological Stress Triggers a Synergism Pattern Switch in Drug Combination Therapy , 2013, PLoS Comput. Biol..

[4]  Peter M. A. Sloot,et al.  Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time , 2010, PloS one.

[5]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[6]  Juanita Lopez,et al.  Combine and conquer: challenges for targeted therapy combinations in early phase trials , 2017, Nature Reviews Clinical Oncology.

[7]  Zhiwei Cao,et al.  Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer , 2015, Nature Communications.

[8]  Xing Chen,et al.  ASDCD: Antifungal Synergistic Drug Combination Database , 2014, PloS one.

[9]  Jun Zou,et al.  Neighbor communities in drug combination networks characterize synergistic effect. , 2012, Molecular bioSystems.

[10]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[11]  Jun Liu,et al.  Fusion of core pathways reveals a horizontal synergistic mechanism underlying combination therapy. , 2011, European journal of pharmacology.

[12]  Peter J. Park,et al.  Systematic Identification of Synergistic Drug Pairs Targeting HIV , 2012, Nature Biotechnology.

[13]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[14]  M. Held,et al.  Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. , 2013, Cancer discovery.

[15]  Feng Xu,et al.  Therapeutic target database update 2014: a resource for targeted therapeutics , 2013, Nucleic Acids Res..

[16]  Susanne May,et al.  Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance , 2008, AIDS.

[17]  Casey S Greene,et al.  Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivity , 2013, Genome Medicine.

[18]  Kenneth C. Anderson,et al.  Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma , 2010, Molecular Cancer Therapeutics.

[19]  Paola Lecca,et al.  Biological network inference for drug discovery. , 2013, Drug discovery today.

[20]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[21]  Igor Goryanin,et al.  Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. , 2011, Cellular signalling.

[22]  R Yuan,et al.  Traditional Chinese medicine: an approach to scientific proof and clinical validation. , 2000, Pharmacology & therapeutics.

[23]  Xing-Ming Zhao,et al.  Exploring drug combinations in genetic interaction network , 2012, BMC Bioinformatics.

[24]  Cheng Luo,et al.  Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors. , 2013, Bioorganic & medicinal chemistry.

[25]  Yi Xiong,et al.  PDC-SGB: Prediction of effective drug combinations using a stochastic gradient boosting algorithm. , 2017, Journal of theoretical biology.

[26]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[27]  Jörn Lötsch,et al.  Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. , 2011, Drug discovery today.

[28]  Andreas Bender,et al.  Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. , 2016, Drug discovery today.

[29]  Jianfeng Pei,et al.  Understanding traditional Chinese medicine anti-inflammatory herbal formulae by simulating their regulatory functions in the human arachidonic acid metabolic network. , 2013, Molecular bioSystems.

[30]  Pablo Carbonell,et al.  Overcoming drug resistance through in silico prediction. , 2014, Drug discovery today. Technologies.

[31]  Xiaobo Zhou,et al.  Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach , 2014, Bioinform..

[32]  Xin Chen,et al.  DCDB 2.0: a major update of the drug combination database , 2014, Database J. Biol. Databases Curation.

[33]  David J Harrison,et al.  Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. , 2012, Cellular signalling.

[34]  Xiaobo Zhou,et al.  Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts , 2015, PloS one.

[35]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[36]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[37]  Devadasan Velmurugan,et al.  Identification of Natural Compound Inhibitors for Multidrug Efflux Pumps of Escherichia coli and Pseudomonas aeruginosa Using In Silico High-Throughput Virtual Screening and In Vitro Validation , 2014, PloS one.

[38]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds , 2014, Nature Biotechnology.

[39]  Victor Guallar,et al.  Computational Prediction of HIV-1 Resistance to Protease Inhibitors , 2016, J. Chem. Inf. Model..

[40]  Yair Benita,et al.  An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies , 2016, Molecular Cancer Therapeutics.

[41]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[42]  Bo Zhang,et al.  Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.

[43]  Zsolt Bikádi,et al.  Predicting substrates of the human breast cancer resistance protein using a support vector machine method , 2013, BMC Bioinformatics.

[44]  P. Aloy,et al.  Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer. , 2017, Cancer research.

[45]  Jun Liu,et al.  Convergent and Divergent Pathways Decoding Hierarchical Additive Mechanisms in Treating Cerebral Ischemia–Reperfusion Injury , 2014, CNS neuroscience & therapeutics.

[46]  Remy Chait,et al.  Optimal Drug Synergy in Antimicrobial Treatments , 2010, PLoS Comput. Biol..

[47]  Laleh Soltan Ghoraie,et al.  Predictive approaches for drug combination discovery in cancer , 2018, Briefings Bioinform..

[48]  U. Alon,et al.  Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.

[49]  Concha Bielza,et al.  Predicting human immunodeficiency virus inhibitors using multi-dimensional Bayesian network classifiers , 2013, Artif. Intell. Medicine.

[50]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[51]  Xing-Ming Zhao,et al.  The drug cocktail network , 2012, BMC Systems Biology.

[52]  Paul Shinn,et al.  Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.

[53]  Michelle S. Scott,et al.  Chemogenomic profiling predicts antifungal synergies , 2009, Molecular systems biology.

[54]  Chris Sander,et al.  Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.

[55]  Hao Wang,et al.  Network Understanding of Herb Medicine via Rapid Identification of Ingredient-Target Interactions , 2014, Scientific Reports.

[56]  Kyoung Mii Park,et al.  CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.

[57]  Adam L Cohen,et al.  A genomic approach to predict synergistic combinations for breast cancer treatment , 2011, The Pharmacogenomics Journal.

[58]  Giovanni Ulivi,et al.  Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization , 2009, Bioinform..

[59]  Xing Chen,et al.  NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning , 2016, PLoS Comput. Biol..

[60]  STC Wong,et al.  DIGRE: Drug-Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects , 2015, CPT: pharmacometrics & systems pharmacology.

[61]  Oliver Werz,et al.  Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.

[62]  Jianxin Chen,et al.  Large-scale exploration and analysis of drug combinations , 2015, Bioinform..

[63]  Lei Huang,et al.  DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..

[64]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[65]  R. Sun,et al.  Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm , 2008, Proceedings of the National Academy of Sciences.

[66]  Karen A. Ryall,et al.  Systems biology approaches for advancing the discovery of effective drug combinations , 2015, Journal of Cheminformatics.

[67]  Soo-Ah Park,et al.  Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim , 2014, BMC Cancer.

[68]  Paul Shinn,et al.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia , 2015, Retrovirology.

[69]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[70]  Ge-Fei Hao,et al.  Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors. , 2010, The journal of physical chemistry. B.

[71]  Matthias Rarey,et al.  Beyond the Virtual Screening Paradigm: Structure-Based Searching for New Lead Compounds , 2009, J. Chem. Inf. Model..

[72]  Simon P. Langdon,et al.  Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations , 2014, Front. Oncol..

[73]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[74]  István A. Kovács,et al.  Drug-therapy networks and the prediction of novel drug targets , 2008, Journal of biology.